Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

about

Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

P2860

Q43991565-D5C6CAC9-139F-4DE3-B589-6CFAD50A8F06 Q55022142-2BB3FBDE-90E7-45E2-9C73-4E3315A54B6F

P2860

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

Item

http://www.wikidata.org/entity/Q39207696

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@en

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@nl

type

Item

label

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@en

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@nl

prefLabel

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@en

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@nl

P1476

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

@en

P2093

James C Tsai

http://www.w3.org/2001/XMLSchema#string

Ji Liu

http://www.w3.org/2001/XMLSchema#string

Louise J Lu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Medical versus surgical interventions for open angle glaucoma

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.

Prevalence of open-angle glaucoma among adults in the United States.

Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.

Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28356898

http://www.w3.org/2001/XMLSchema#string

P921

open-angle glaucoma

P932

5369028

http://www.w3.org/2001/XMLSchema#string

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

about

P2860

P2860

Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P433

P478

P5008

P577

P698

P921

P932

P1433

P1476

P2093

P275

P2860

P304

P31

P433

P478

P5008

P577

P698

P921

P932